My research program is directed toward understanding the genomics and pharmacogenomics of cardiovascular disease.
The overarching goal of our lab is to understand how common and rare genetic variation in individuals and populations contributes to variable disease susceptibility and drug response and toxicity, and then translate this knowledge to improved patient-centered care. We conduct studies across a range of populations using a variety of techniques. A major interests is leveraging the power of the electronic medical record (EMR) for genomic and pharmacogenomics studies, and in 2014 we created the Vanderbilt System for EMR-based Research in Cardiovascular Health (V-SERCH). Part of the Cardiovascular Division, V-SERCH is dedicated to developing validated algorithms and tools for conducting research in the EMR environment. Recent projects include a genome-wide association study (GWAS) of susceptibility to chemotherapy related cardiotoxicity that has identified potentially novel mechanisms that are being explored using in vitro models and human clinical cohorts. We also leading an institutional pilot project that extends Vanderbilt’s BioVU biorepository, which links DNA samples to de-identified clinical records, to include plasma samples from heart failure subjects for biomarker discovery.